Ardelyx
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ardelyx sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Ardelyx: 25 sponsored US clinical trials, 3 recruiting.
Ardelyx sponsors 25 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 21 completed. 9 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Irritable Bowel Syndrome With Constipation (IBS-C), with 2 trials.
Top-decile sponsor footprint
Ardelyx ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
NCT07382167
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
NCT06553547
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
NCT06203444
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
NCT04780841
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
NCT04549597
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
NCT03988920
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
NCT03824587
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
NCT03427125
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
NCT03018067
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
NCT02727751
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
NCT02675998
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
NCT02686138
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
NCT02621892
To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers
NCT02140268
To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers
NCT02140281
Dose Finding Study to Treat High Phosphate Levels in the Blood.
NCT02081534
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01923428
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
NCT02176252
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT01847092
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
NCT02346890
D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects
NCT02226783
A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
NCT02249936
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
NCT01764854
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01340053
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Phase 4 | 2 |
What is open in the Ardelyx pipeline
3 recruiting of 25 indexed (12% open); 21 completed (84%).
Phase mix: 9 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Irritable Bowel Syndrome With Constipation (IBS-C) (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ardelyx: open-pipeline peers nationwide
Peers matched on 25 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Ardelyx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
- Fisher and Paykel Healthcare · 25 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- Takeda · 12% recruiting · 408 trials
- East Carolina University · 12% recruiting · 58 trials
- National Institute of Dental and Craniofacial Research (NIDCR) · 12% recruiting · 91 trials
Related
What to do with this Ardelyx page
25 registered trials is a research-attention snapshot, not an endorsement of Ardelyx or any single study.
- 3 of Ardelyx's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Irritable Bowel Syndrome With Constipation (IBS-C) is the condition Ardelyx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Irritable Bowel Syndrome With Constipation (IBS-C) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ardelyx pipeline card: 25 registered trials from official public datasets.Report a data error.